Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Inc.

Tactical Resources Corp. ( ($TSE:RARE) ) has provided an update. Tactical Resources Corp., a U.S.-focused rare earth elements developer advancing t...

Tactical Resources Completes Plum Merger, Readies Nasdaq Debut to Advance Texas Rare Earths Project

In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $33....

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Stevanato Group (STVN), Ultragenyx Pharmaceutical ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (STVN), Ultragenyx Pharmaceutical (RARE) and PROCEPT BioRobotics (PRCT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceut...

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spyre Therapeutics (SYRE), Ultragenyx Pharmaceutic...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (SYRE), Ultragenyx Pharmaceutical (RARE) and Bruker (BRKR)

Barclays analyst Eliana Merle maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $43.00. According to TipRanks, M...

Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE) and Danaher (DHR) w...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RARE	$25.30	-3.18%	254.66K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RARE	$25.30	-3.2%	254.66K
3
4
5
6

RARE

Get Ultragenyx Pharmaceutical Inc. Data in Excel

Get Ultragenyx Pharmaceutical Inc. Data in Excel